$NBIO - "This patent further validates the value of PTB as a unique biotechnology asset," remarked Nascent CEO, Sean Carrick. "It also extends our IP footprint internationally, opening up new market potential, expanding the upside value proposition of PTB commercially.
https://finance.yahoo.com/news/nascent-biotec...00461.html